Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05019690

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Apatinib Mesylate Combined with Albumin-bound Paclitaxel for Second-line Treatment of Advanced Triple Negative Breast Cancer:a Single-arm,exploratory Clinical Study

Sponsor: Fujian Cancer Hospital

Conditions Advanced Triple Negative Breast Cancer

Interventions Albumin-Bound Paclitaxel Apatinib Mesylate

Updated 5 times since 2021 Last updated: Sep 6, 2024 Started: Oct 1, 2021 Primary completion: Dec 1, 2024 Completion: Jun 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Advanced Triple Negative Breast Cancer and is currently actively recruiting participants. Fujian Cancer Hospital leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Oct 2024 — Present [monthly]

Recruiting PHASE1/PHASE2

Status: Unknown → Recruiting
Sep 2024 — Oct 2024 [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Feb 2024 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Not Yet Recruiting → Unknown Status
Sep 2021 — Feb 2024 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fujian Cancer Hospital

Data source: Fujian Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fuzhou, China